Browsing publications by Michael Batey

Newcastle AuthorsTitleYear
Dr Britta Vormoor
Henrike Knizia
Michael Batey
Dr Petra Dildey
Abhishek Sharma
et al.
Development of a Preclinical Orthotopic Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone Disease Using Advanced In Vivo Imaging2014
Dr Joanne Munck
Michael Batey
Dr Yan Zhao
Dr Celine Cano
Dr Michele Tavecchio
et al.
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K2012
Michael Batey
Dr Yan Zhao
Dr Helen Maitland
Professor Hing Leung
Professor Andy Hall
et al.
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma2011
Michael Batey
Dr Andrew Pike
Dr Julie Irving
Professor Herbie Newell
Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models2011
Patricia Garrido Castro
Dr Simon Bomken
Elda Latif
Michael Batey
Hesta McNeill
et al.
ANGIOPOIETIN1 a Novel Factor Implicated In MLL Rearranged Acute Lymphoblastic Leukemia and Regulated In a Fusion Gene Dependent Manner2010
Elda Latif
Michael Batey
Hesta McNeill
Professor Josef Vormoor
Professor Olaf Heidenreich
et al.
ANGIOPOIETIN1-a Novel Factor Implicated In MLL-Rearranged Acute Lymphoblastic Leukemia and Regulated In a Fusion Gene-Dependent Manner2010
Henrike Knizia
Michael Batey
Gilberto de Almeida
Dr Ross Maxwell
Dr Petra Dildey
et al.
Development of an orthotopic model for human malignant bone diseases in immunocompromised NOD.Cg-PrkdcscidIl2rgtmlwjl/szj (NSG) mice2010
Michael Batey
Professor Herbie Newell
Professor Nicola Curtin
Chemosensitisation of cancer cells by KU-0060648, a potent and selective inhibitor of DNA-PK [abstract]2008
Michael Batey
Dr Amy Peasland
Dr Julie Irving
Professor Herbie Newell
Development of inhibitors of the fibroblast growth factor receptor (FGFR) kinase using a fragment based approach2008
Michael Batey
Dr Helen Maitland
Professor Hing Leung
Professor Andy Hall
Professor Graham Jackson
et al.
In vitro activity of the multi targeted receptor tyrosine kinase inhibitor sunitinib against multiple myeloma cell lines is not predictive of in vivo xenograft response2008
123